Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini
Journal of Endocrinological Investigation (2021) Vol. 44, Iss. 7, pp. 1379-1386
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

COVID-19 and Diabetes
Awadhesh Kumar Singh, Kamlesh Khunti
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 129-147
Closed Access | Times Cited: 80
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, et al.
Metabolism (2022) Vol. 131, pp. 155196-155196
Open Access | Times Cited: 69
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Tiantian Han, Shaodi Ma, Chenyu Sun, et al.
Archives of Medical Research (2021) Vol. 53, Iss. 2, pp. 186-195
Open Access | Times Cited: 50
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 34
COVID-19 Infections in Gonads: Consequences on Fertility?
Nicole Bechmann, Umberto Macciò, Reham Kotb, et al.
Hormone and Metabolic Research (2022) Vol. 54, Iss. 08, pp. 549-555
Open Access | Times Cited: 29
Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?
Basil Mohammed Alomair, Hayder M. Al‐kuraishy, Ali K. Albuhadily, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 6, pp. 2411-2415
Open Access | Times Cited: 23
Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists
И. И. Дедов, Н. Г. Мокрышева, М. В. Шестакова, et al.
Diabetes Mellitus (2022) Vol. 25, Iss. 1, pp. 27-49
Open Access | Times Cited: 19
Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, et al.
Journal of Diabetes (2023) Vol. 15, Iss. 2, pp. 86-96
Open Access | Times Cited: 13
Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19
Łukasz Lewandowski, Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 605-605
Open Access | Times Cited: 4
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
Dimitrios Patoulias, Michael Doumas
Endocrinology and Metabolism (2021) Vol. 36, Iss. 4, pp. 904-908
Open Access | Times Cited: 25
A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19
Ran Abuhasira, Irit Ayalon‐Dangur, Neta Zaslavsky, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 24
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary care diabetes (2021) Vol. 16, Iss. 1, pp. 162-167
Open Access | Times Cited: 21
Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections
Shailendra Mani, Anupamjeet Kaur, Kamini Jakhar, et al.
International Journal of Biological Macromolecules (2023) Vol. 245, pp. 125444-125444
Open Access | Times Cited: 9
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Leszek Czupryniak, Dror Dicker, Roger Lehmann, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 20
Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme
Anjing Chen, Wenguo Zhao, Xiaolong Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID‐19
Andrea Mario Bolla, Cristian Loretelli, Laura Montefusco, et al.
Diabetes/Metabolism Research and Reviews (2022) Vol. 38, Iss. 7
Open Access | Times Cited: 13
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis
Giulia Ferrannini, Lars H. Lund, Lina Benson, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2022) Vol. 9, Iss. 1, pp. 10-17
Open Access | Times Cited: 12
Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus
Ayça Elibol, Didem Eren, Macide Deniz Erdoğan, et al.
Primary care diabetes (2021) Vol. 15, Iss. 5, pp. 806-812
Open Access | Times Cited: 15
Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19
Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2624-2624
Open Access | Times Cited: 11
Managing diabetes in diabetic patients with COVID: where do we start from?
Angelo Avogaro, Benedetta Maria Bonora, Gian Paolo Fadini
Acta Diabetologica (2021) Vol. 58, Iss. 11, pp. 1441-1450
Open Access | Times Cited: 14
Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study
Rıfat Emral, Cem Haymana, İbrahim Demirci, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 11, pp. 2857-2870
Open Access | Times Cited: 14
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2022) Vol. 130, Iss. S 01, pp. S80-S112
Open Access | Times Cited: 9
Efficacy and Safety of Sitagliptin in the Treatment of COVID-19
Ehab Mudher Mikhael, Siew Chin Ong, Siti Maisharah Sheikh Ghadzi
Journal of Pharmacy Practice (2022) Vol. 36, Iss. 4, pp. 980-987
Open Access | Times Cited: 8
COVID-19 Outcomes and Diabetes Mellitus: A Comprehensive Multicenter Prospective Cohort Study
Karolina Akinosoglou, Georgios Schinas, Evanthia Bletsa, et al.
Microorganisms (2023) Vol. 11, Iss. 6, pp. 1416-1416
Open Access | Times Cited: 4
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, et al.
World Journal of Virology (2022) Vol. 11, Iss. 6, pp. 399-410
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top